Clarus spearheads a big, $150M raise so Galera can flip the PhIII card on its new drug to treat radiation effects
Anyone looking for solid evidence of the kind of impact the new, flush funding environment — along with a more accommodating FDA — is having on biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
